MX2024006371A - Métodos para tratar trastornos neurológicos. - Google Patents

Métodos para tratar trastornos neurológicos.

Info

Publication number
MX2024006371A
MX2024006371A MX2024006371A MX2024006371A MX2024006371A MX 2024006371 A MX2024006371 A MX 2024006371A MX 2024006371 A MX2024006371 A MX 2024006371A MX 2024006371 A MX2024006371 A MX 2024006371A MX 2024006371 A MX2024006371 A MX 2024006371A
Authority
MX
Mexico
Prior art keywords
methods
neurological disorders
treating neurological
treating
fesoterodine
Prior art date
Application number
MX2024006371A
Other languages
English (en)
Spanish (es)
Inventor
Michael Wood
James Lillie
Original Assignee
Maplight Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maplight Therapeutics Inc filed Critical Maplight Therapeutics Inc
Publication of MX2024006371A publication Critical patent/MX2024006371A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2024006371A 2021-11-24 2022-11-23 Métodos para tratar trastornos neurológicos. MX2024006371A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163283140P 2021-11-24 2021-11-24
US202263416745P 2022-10-17 2022-10-17
PCT/US2022/080429 WO2023097276A1 (en) 2021-11-24 2022-11-23 Methods of treating neurological disorders

Publications (1)

Publication Number Publication Date
MX2024006371A true MX2024006371A (es) 2024-07-15

Family

ID=86540399

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024006371A MX2024006371A (es) 2021-11-24 2022-11-23 Métodos para tratar trastornos neurológicos.

Country Status (9)

Country Link
US (1) US20250032460A1 (https=)
EP (1) EP4436564A4 (https=)
JP (1) JP2024541770A (https=)
KR (1) KR20240110642A (https=)
AU (1) AU2022396530A1 (https=)
CA (1) CA3239067A1 (https=)
IL (1) IL313067A (https=)
MX (1) MX2024006371A (https=)
WO (1) WO2023097276A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3061821T (pt) * 2009-07-22 2019-09-05 PureTech Health LLC Composições para tratamento de distúrbios melhorados por ativação de recetores muscarínicos
US8853219B2 (en) * 2010-01-11 2014-10-07 Neurosolis, Inc. Compounds and compositions for cognition-enhancement, methods of making, and methods of treating
WO2012033956A1 (en) * 2010-09-08 2012-03-15 Mithridion, Inc. Cognition enhancing compounds and compositions, methods of making, and methods of treating
US9012489B2 (en) * 2011-08-03 2015-04-21 Boehringer Ingelheim International Gmbh Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament
CA2978214A1 (en) * 2015-03-06 2016-09-15 Chase Pharmaceuticals Corporation Peripheral-anticholinergic muscarinic agonist combination

Also Published As

Publication number Publication date
CA3239067A1 (en) 2023-06-01
US20250032460A1 (en) 2025-01-30
JP2024541770A (ja) 2024-11-12
EP4436564A4 (en) 2025-10-22
EP4436564A1 (en) 2024-10-02
IL313067A (en) 2024-07-01
AU2022396530A1 (en) 2024-06-13
KR20240110642A (ko) 2024-07-15
WO2023097276A1 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
MX2023005725A (es) Metodo para el tratamiento de la enfermedad de parkinson.
PH12021550176A1 (en) Method for treating epilepsy
MX2023002323A (es) Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
PH12021551463A1 (en) Modulators of hsd17b13 expression
WO2021089768A3 (en) Treatment and prevention of a neurodegenerative disorder
MX2022011518A (es) Metodos para tratar deambulacion asociada a proteinopatia.
PH12018500430A1 (en) Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia
AU2018243836A1 (en) Gut-selective sequestering agents for the treatment and prevention of autism and related disorders
MX2020002884A (es) Método y composición neuroprotectora mejorada para tratar afecciones neurológicas.
MX2020012940A (es) Metodos de uso de moduladores de empalme.
CR20230121A (es) Tratamiento de la enfermedad de parkinson
WO2023077125A3 (en) Azepino-indoles for the treatment of neurological and psychiatric disorders
MX2024006371A (es) Métodos para tratar trastornos neurológicos.
MX2024000701A (es) Metodos de tratamiento de la enfermedad de alzheimer.
MX2021001264A (es) Métodos para tratar la vejiga hiperactiva con el uso de trospio.
MX2022012632A (es) Uso de inhibidores del bromodominio para el tratamiento de la enfermedad de huntington.
MX2020007817A (es) Prevención y tratamiento del trastorno del sueño.
PH12021551975A1 (en) Use of vibegron to treat overactive bladder
BR112021010856A2 (pt) Vibegron para o tratamento de sintomas de bexiga hiperativa
SA521431094B1 (ar) مركبات علاج الاضطرابات العصبية والعضلية
MX2025008168A (es) Métodos de tratamiento de los síntomas del trastorno del espectro autista.
WO2020247819A3 (en) Methods of treatment with aminolevulinic acid synthase 2 (alas2) modulators
PH12020551527A1 (en) Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders
MX2021005776A (es) Formulaciones farmaceuticas para administracion subcutanea.
WO2020236010A8 (en) Fatty acid compounds for prevention and treatment of neurodegenerative disorders